



## **CORINDUS VASCULAR ROBOTICS ADDED TO RUSSELL INDEXES**

**WALTHAM, MA, June 25, 2015** – [Corindus Vascular Robotics, Inc. \[NYSE MKT: CVRS\]](#), a leading developer of precision vascular robotics, announced today that the company has been added to the Russell Global and Russell 2000® Indexes. This inclusion will become effective upon the close of trading on June 26 when the Russell Investment Group reconstitutes its comprehensive set of U.S. and global indexes, according to a preliminary list of additions recently posted. Annual reconstitution of Russell U.S. Indexes captures the largest U.S. stocks as of the end of May 2015, ranking them by total market capitalizations.

"We are extremely pleased to note our addition to the prestigious Russell Indexes," said David M. Handler, Chief Executive Officer and President. "We expect the enhanced profile generated by the Russell Indexes will enable us to increase awareness of Corindus and reach a broader investor base."

Russell Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Each June, the entire family of Russell U.S. and global equity indexes are realigned and recalibrated to reflect market changes in the past year. This year's rebalance impacts approximately \$5.7 trillion in assets benchmarked to and more than \$800 billion in assets invested in products based on them.

The Russell 2000 Index is a subset of the Russell 3000 Index. It includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership. The Russell 2000 Index is constructed to provide a comprehensive and unbiased small-cap barometer and is completely reconstituted annually to ensure larger stocks do not distort the performance and characteristics of the true small-cap opportunity set. This weighted index by market capitalization now represents approximately 98% of the investable U.S. equity market. The Russell Global Indexes reflect the performance of over 10,000 securities in 47 countries. Membership in these indexes is updated annually, and remains in place for one year.

### **About Corindus Vascular Robotics, Inc.**

[Corindus Vascular Robotics, Inc.](#) is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The Company's FDA-cleared CorPath System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help physicians potentially provide better clinical outcomes and minimize the costs associated with complications through improper stent placement with manual PCI procedures. Corindus Vascular Robotics stands behind its product with its unique \$1,000 hospital credit "One Stent Program." For additional information, visit [www.corindus.com](http://www.corindus.com), and follow @CorindusInc.

### **About FTSE Russell**

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 80 countries, covering 98% of the investable market globally and trading on over 25 exchanges worldwide. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Leading asset owners, asset managers, ETF providers and investment banks use FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance. FTSE Russell is also focused on index innovation and client collaboration as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit [www.ftserussell.com](http://www.ftserussell.com).

*Except for the factual information contained herein, the statement regarding the company's belief that the enhanced profile generated by the Russell Indexes will enable the company to increase awareness of Corindus Vascular Robotics and reach a broader investor base, is a forward-looking statement within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. This forward-looking statement is subject to risks and uncertainties that may cause actual results to differ materially, including but not limited to the actual effect of the addition to the Russell Indexes; the rate of adoption of the CorPath System and the rate of use of CorPath Cassettes; risks associated with market acceptance, including pricing and reimbursement; Corindus Vascular Robotics' ability to enforce its intellectual property rights; the need for additional funds to support operations; the ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend sales; and the effect of credit, financial and economic conditions on capital spending by potential customers. This forward-looking statement is subject to risks and uncertainties that may cause actual results to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus Vascular Robotics' beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of Corindus Vascular Robotics. More information on potential factors that could affect Corindus Vascular Robotics' financial results is included from time to time in the "Forward-Looking Statements," "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Corindus Vascular Robotics' periodic and current filings with the SEC, as well as those discussed under the "Risk Factors" and "Forward-Looking Statements" section of Corindus Vascular Robotics' Annual Report on Form 10-K filed with the SEC on March 30, 2015 and available on its website at <http://www.corindus.com/about-corindus/investor-relations>. Forward-looking statements speak only as of the date they are made and Corindus Vascular Robotics undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, that occur after that date.*

###

**Media Contacts:**

Corindus Vascular Robotics, Inc.

Brett Prince

(508) 653-3335 ext. 231

[brett.prince@corindus.com](mailto:brett.prince@corindus.com)

Emma Ludwin

203-504-8230 ext. 107

[corindus@knbpr.com](mailto:corindus@knbpr.com)